Literature DB >> 25695959

Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance.

Hannah H Lee1, Brenda F Leake1, Wendy Teft2, Rommel G Tirona2, Richard B Kim2, Richard H Ho3.   

Abstract

The antimicrotubular agent docetaxel is a widely used chemotherapeutic drug for the treatment of multiple solid tumors and is predominantly dependent on hepatic disposition. In this study, we evaluated drug uptake transporters capable of transporting radiolabeled docetaxel. By screening an array of drug uptake transporters in HeLa cells using a recombinant vaccinia-based method, five organic anion-transporting polypeptides (OATP) capable of docetaxel uptake were identified: OATP1A2, OATP1B1, OATP1B3, OATP1C1, and Oatp1b2. Kinetic analysis of docetaxel transport revealed similar kinetic parameters among hepatic OATP1B/1b transporters. An assessment of polymorphisms (SNPs) in SLCO1B1 and SLCO1B3 revealed that a number of OATP1B1 and OATP1B3 variants were associated with impaired docetaxel transport. A Transwell-based vectorial transport assay using MDCKII stable cells showed that docetaxel was transported significantly into the apical compartment of double-transfected (MDCKII-OATP1B1/MDR1 and MDCKII-OATP1B3/MDR1) cells compared with single-transfected (MDCKII-OATP1B1 and MDCKII-OATP1B3) cells (P < 0.05) or control (MDCKII-Co) cells (P < 0.001). In vivo docetaxel transport studies in Slco1b2(-/-) mice showed approximately >5.5-fold higher plasma concentrations (P < 0.01) and approximately 3-fold decreased liver-to-plasma ratio (P < 0.05) of docetaxel compared with wild-type (WT) mice. The plasma clearance of docetaxel in Slco1b2(-/-) mice was 83% lower than WT mice (P < 0.05). In conclusion, this study demonstrates the important roles of OATP1B transporters to the hepatic disposition and clearance of docetaxel, and supporting roles of these transporters for docetaxel pharmacokinetics. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25695959      PMCID: PMC4394048          DOI: 10.1158/1535-7163.MCT-14-0547

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  46 in total

1.  Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide.

Authors:  Wei Zhang; Yi-Jing He; Chun-Ting Han; Zhao-Qian Liu; Qing Li; Lan Fan; Zhi-Rong Tan; Wei-Xia Zhang; Bang-Ning Yu; Dan Wang; Dong-Li Hu; Hong-Hao Zhou
Journal:  Br J Clin Pharmacol       Date:  2006-06-23       Impact factor: 4.335

2.  Phase I and II metabolism and MRP2-mediated export of bosentan in a MDCKII-OATP1B1-CYP3A4-UGT1A1-MRP2 quadruple-transfected cell line.

Authors:  C Fahrmayr; J König; D Auge; M Mieth; K Münch; J Segrestaa; T Pfeifer; A Treiber; Mf Fromm
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

3.  A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane.

Authors:  J König; Y Cui; A T Nies; D Keppler
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2000-01       Impact factor: 4.052

4.  Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide.

Authors:  J König; Y Cui; A T Nies; D Keppler
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

5.  Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel.

Authors:  Michael C Cox; Jennifer Low; James Lee; Janice Walshe; Neelima Denduluri; Arlene Berman; Matthew G Permenter; William P Petros; Douglas K Price; William D Figg; Alex Sparreboom; Sandra M Swain
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

6.  Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans.

Authors:  R G Tirona; B F Leake; G Merino; R B Kim
Journal:  J Biol Chem       Date:  2001-07-26       Impact factor: 5.157

7.  Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2).

Authors:  Makoto Sasaki; Hiroshi Suzuki; Kousei Ito; Takaaki Abe; Yuichi Sugiyama
Journal:  J Biol Chem       Date:  2001-12-17       Impact factor: 5.157

Review 8.  Biochemistry of multidrug resistance mediated by the multidrug transporter.

Authors:  M M Gottesman; I Pastan
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

9.  Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms.

Authors:  A Tran; V Jullien; J Alexandre; E Rey; F Rabillon; V Girre; V Dieras; G Pons; F Goldwasser; J M Tréluyer
Journal:  Clin Pharmacol Ther       Date:  2006-05-02       Impact factor: 6.875

Review 10.  Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity.

Authors:  Rafid Salim Jabir; Rakesh Naidu; Muhammad Azrif Bin Ahmad Annuar; Gwo Fuang Ho; Murali Munisamy; Johnson Stanslas
Journal:  Pharmacogenomics       Date:  2012-12       Impact factor: 2.533

View more
  14 in total

Review 1.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

2.  Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance.

Authors:  Hannah H Lee; Brenda F Leake; Richard B Kim; Richard H Ho
Journal:  Mol Pharmacol       Date:  2016-10-24       Impact factor: 4.436

Review 3.  Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1).

Authors:  Hannah H Lee; Richard H Ho
Journal:  Br J Clin Pharmacol       Date:  2017-01-19       Impact factor: 4.335

Review 4.  Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology.

Authors:  Rachael R Schulte; Richard H Ho
Journal:  Mol Pharmacol       Date:  2019-02-19       Impact factor: 4.436

5.  Genotyping of the OATP1B1 c. 521 T>C Polymorphism from the Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Specimens: an Optimized Protocol.

Authors:  Alexandra R Crowe; Jonathan Miller; Wei Yue
Journal:  Bio Protoc       Date:  2019-08-20

6.  Characterization of Liver- and Cancer-type-Organic Anion Transporting Polypeptide (OATP) 1B3 Messenger RNA Expression in Normal and Cancerous Human Tissues.

Authors:  Khondoker Alam; Taleah Farasyn; Kai Ding; Wei Yue
Journal:  Drug Metab Lett       Date:  2018

7.  OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity.

Authors:  Alix F Leblanc; Jason A Sprowl; Paola Alberti; Alessia Chiorazzi; W David Arnold; Alice A Gibson; Kristen W Hong; Marissa S Pioso; Mingqing Chen; Kevin M Huang; Vamsi Chodisetty; Olivia Costa; Tatiana Florea; Peter de Bruijn; Ron H Mathijssen; Raquel E Reinbolt; Maryam B Lustberg; Lara E Sucheston-Campbell; Guido Cavaletti; Alex Sparreboom; Shuiying Hu
Journal:  J Clin Invest       Date:  2018-01-16       Impact factor: 14.808

8.  Data-Driven Ensemble Docking to Map Molecular Interactions of Steroid Analogs with Hepatic Organic Anion Transporting Polypeptides.

Authors:  Alzbeta Tuerkova; Orsolya Ungvári; Réka Laczkó-Rigó; Erzsébet Mernyák; Gergely Szakács; Csilla Özvegy-Laczka; Barbara Zdrazil
Journal:  J Chem Inf Model       Date:  2021-06-09       Impact factor: 4.956

9.  Differential Associations of SLCO Transporters with Prostate Cancer Aggressiveness between African Americans and European Americans.

Authors:  Li Tang; Qianqian Zhu; Zinian Wang; Clayton M Shanahan; Jeannette T Bensen; Elizabeth T H Fontham; Gary J Smith; Elena A Pop; Gissou Azabdaftari; James L Mohler; Yue Wu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-02-22       Impact factor: 4.090

10.  Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions.

Authors:  Jason T Anderson; Kevin M Huang; Maryam B Lustberg; Alex Sparreboom; Shuiying Hu
Journal:  Rev Physiol Biochem Pharmacol       Date:  2022       Impact factor: 7.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.